PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

JAN 3 0 2006 duction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

postitute for form 49/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/507,046		
Filing Date	September 9, 2005		
First Named Inventor	Harald Schlebusch et al.		
Art Unit	1641		
Examiner Name	Unassigned		
Attorney Docket Number	14836-46758		

Examiner C Initials* N	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (# known)}		Figures App	
/4/	1	^{US-} 5,858,361	01-12-1999	Wagner, et al.	
10		US-			
		US-			
		US-			
•		US-			•
		US-			
		US-	- 		
		US-			
		US-	<u> </u>		
		US-			
		US-		•	
		US-			
		US-			
		US-			
	_	US-			
	<u> </u>	US-			
		US-			
	<u> </u>	US-	<u> </u>		
		us-		· · · · · · · · · · · · · · · · · · ·	

ſ		FORE	IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	-0
	<u>.</u>	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	L,
A	2	EP 0 700 305 B1	03-13-1996	Wagner, U. et al.		
\Box	3	WO 94 27637 A	12-08-1994	Schlebusch, H. et al.	pages 3, 7, 14, 17	
	<u> </u>					
	<u> </u>					┷

	· · · · · · · · · · · · · · · · · · ·		
Examiner Signature	6911	Date Considered	2.20.07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/088 (07-05)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
0003010	ne lor lotti (1440). To		•	Application Number	10/507,046
INF	ORMATION	DIS	CLOSURE	Filing Date	September 9, 2005
STA	STATEMENT BY APPLICANT		First Named Inventor	Harald Schlebusch et al.	
	(Use as many sheets as necessary)			Art Unit	1641
(Use as many sneets as necessary)		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	14836-46758

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
M	4	SCHULTES, B. et al.; "Anti-Idiotype induction therapy: Anti-CA125 antibodies (AB3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)"; Cancer Immunology and Immunotherapy; June 1998; pp. 201-212; Vol. 46, No. 4.		
. •(
٠				

Examiner Signature		Elle	Date Considered	2,20,7
AFVANUATED: 1	10-116-1-1	COLUMN TO THE STATE OF THE STAT	O Denverting Absorber	testine if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.